EMA/491310/2024 Corr[1]

European Medicines Agency decision

P/0385/2024

of 25 October 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP08-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

[1] 28 October 2024

European Medicines Agency decision

P/0385/2024

of 25 October 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP08-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[2],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[3],

Having regard to the application submitted by Sanofi B.V. on 8 September 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 September 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency, following a re-examination procedure of the Paediatric Committee's opinion according to Article 25(3) of Regulation (EC) No 1901/2006, has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[2] OJ L 378, 27.12.2006, p.1, as amended.
[3] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for venglustat, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for venglustat, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for venglustat, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Sanofi B.V., 25 Paasheuvelweg, 1105 BP – Amsterdam, The Netherlands.

EMA/PDCO/452470/2024 Corr[1] Corr[2]
Amsterdam, 18 October 2024

Final opinion of the Paediatric Committee on the agreement of a Paediatric Investigation plan and a deferral and a waiver

EMEA-001716-PIP08-23

Scope of the application

Active substance(s):

Venglustat

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Fabry disease

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Sanofi B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sanofi B.V. submitted for agreement to the European Medicines Agency on 8 September 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

An Opinion was adopted by the Paediatric Committee on 6 September 2024 for the above mentioned product. Sanofi B.V. received the Paediatric Committee Opinion on 13 September 2024.

[1] 22 October 2024
[2] 28 October 2024

On 27 September 2024 Sanofi B.V. submitted to the European Medicines Agency a written request, including detailed grounds for re-examination of the Opinion.

The re-examination procedure started on 27 September 2024.

A meeting with the Paediatric Committee took place on 16 October 2024.

Final Opinion

1. The Paediatric Committee, having assessed the detailed grounds for re-examination, in accordance with Article 25(3) of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   1.1. to revise its opinion and

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   1.2. following re-examination, to amend the measures of the paediatric investigation plan.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Fabry disease

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Fabry disease

2.1.1. Indication(s) targeted by the PIP

Treatment of Fabry disease (FD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of small size chewable tablets appropriate to be administered in paediatric patients from 2 years of age and older using doses based on body weight.
Non-clinical studies	**Study 2** Oral gavage pre- and post-natal developmental toxicity study in Sprague-Dawley rats (DPN0381). **Study 3** Oral gavage toxicity study in the juvenile rat (GT-373-TX-23)

	Study 4 Oral gavage toxicity study in the male juvenile rats with an 18-week recovery and a toxicokinetic phase (JUV0046).
Clinical studies	**Study 5** Double-blind, randomized, placebo-controlled trial to evaluate effect of venglustat on neuropathic and abdominal pain symptoms in adolescents from 16 years to less than 18 years of age (and adults) with Fabry disease who are treatment naïve or untreated for at least 6 months prior to screening (EFC17045). **Study 6** Open-label, single arm trial to evaluate safety, pharmacokinetics/pharmacodynamics and activity of venglustat in male and female patients aged from 2 years to less than 18 years with Fabry disease who are treatment naïve, previously treated, or currently receiving an approved therapy for Fabry disease.
Modelling and simulation analyses	**Study 7** Pop-PK model to predict initial paediatric doses to be used in further clinical studies. **Study 8** Pop-PK(/PD) and/or Exposure-Response (E-R) to confirm or modify the paediatric posology compared to the regimen used in clinical trials and to simulate PK and PD to be used as basis for extrapolation and paediatric posology recommendation from age of 2 years to < 18 years.
Other studies	**Study 9** Analysis of pooled data from completed studies including paediatric participants from 2 years to < 18 years including data from all patients, irrespective of condition, having been exposed to venglustat (regardless of the dose, duration of exposure or co-medications) to support safety assessment in paediatric participants.
Extrapolation plan	Studies 6, 7, 8 and 9 are part of the extrapolation plan of efficacy data from adult and adolescent patients (> 16 years of age) to the paediatric population from 2 years to less than 18 years of age with Fabry disease.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.